Pluri Inc. entered into a partnership agreement with ZEO ScientifiX, granting an exclusive U.S. license to its regenerative medicine portfolio in exchange for 41% of ZEO’s equity, Series D preferred stock, and warrants. Pluri will hold board nomination rights and aim for a 50% ownership stake. Separately, the company raised $1 million by issuing common shares and warrants at $1.10 per share to two investors. Additionally, the EIB sold its €27.5 million loan to shareholder Alexandre Weinstein at a discount, with settlement terms pending. Pluri Inc. operates in the biotechnology sector, developing regenerative medicine therapies.
